Later, another non-peptide TpoR agonists were developed that showed efficacy for the treatment of many thrombocytopenia-related conditions such as eltrombopag that was FDA approved for many conditions such as ITP and refractory aplastic anemia, avatrombopag and lusutrombopag that are FDA approved and hetrombopag that is being under investigation currently. This evidence concerns the gene MPL and aplastic anemia.